(Reuters) -German COVID-19 vaccine maker BioNTech on Monday said that its 2025 revenues would likely fall to between 1.7 ...
We’ve learned a lot about COVID-19 over the last five years, but big questions remain. Recent federal actions may hinder the disease’s management.
BioNTech SE exceeded earnings expectations with strong oncology pipeline development, despite reduced vaccine revenue.
CLEVELAND, Ohio — The measles outbreak in Texas and New Mexico has resulted in a second death, leaving many Ohioans wondering ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback